Bleeding risk and P2Y12-inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-center cohort study.
Mia R JacobsenReza JabbariThomas EngstrømE L GroveCharlotte GlingeFrants PedersenLene HolmvangLars Valeur KøberC Torp-PedersenM MaengK VeienP FreemanM G CharlotH KelbækRikke SørensenPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
One-third of PCI-treated all-comer patients with STEMI were at HBR according to the PRECISE-DAPT score and more often treated with potent P2Y12-inhibitors instead of clopidogrel. Thus, ischaemic risk may be weighted over bleeding risk in STEMI patients at HBR.
Keyphrases
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- coronary artery bypass
- newly diagnosed
- magnetic resonance imaging
- heart failure
- left ventricular
- contrast enhanced